» Articles » PMID: 35814774

Revisiting IgG Antibody Reactivity to Epstein-Barr Virus in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Its Potential Application to Disease Diagnosis

Abstract

Infections by the Epstein-Barr virus (EBV) are often at the disease onset of patients suffering from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). However, serological analyses of these infections remain inconclusive when comparing patients with healthy controls (HCs). In particular, it is unclear if certain EBV-derived antigens eliciting antibody responses have a biomarker potential for disease diagnosis. With this purpose, we re-analyzed a previously published microarray data on the IgG antibody responses against 3,054 EBV-related antigens in 92 patients with ME/CFS and 50 HCs. This re-analysis consisted of constructing different regression models for binary outcomes with the ability to classify patients and HCs. In these models, we tested for a possible interaction of different antibodies with age and gender. When analyzing the whole data set, there were no antibody responses that could distinguish patients from healthy controls. A similar finding was obtained when comparing patients with non-infectious or unknown disease trigger with healthy controls. However, when data analysis was restricted to the comparison between HCs and patients with a putative infection at their disease onset, we could identify stronger antibody responses against two candidate antigens (EBNA4_0529 and EBNA6_0070). Using antibody responses to these two antigens together with age and gender, the final classification model had an estimated sensitivity and specificity of 0.833 and 0.720, respectively. This reliable case-control discrimination suggested the use of the antibody levels related to these candidate viral epitopes as biomarkers for disease diagnosis in this subgroup of patients. To confirm this finding, a follow-up study will be conducted in a separate cohort of patients.

Citing Articles

Immunologic and inflammatory consequences of SARS-CoV-2 infection and its implications in renal disease.

Naiditch H, Betts M, Larman H, Levi M, Rosenberg A Front Immunol. 2025; 15:1376654.

PMID: 40012912 PMC: 11861071. DOI: 10.3389/fimmu.2024.1376654.


EBNA-1 and VCA-p18 immunoglobulin markers link Epstein-Barr virus immune response and brain's myelin content to fatigue in a community-dwelling cohort.

Gayer M, Xu Z, Hodel F, Preisig M, Strippoli M, Vollenweider P Brain Behav Immun Health. 2024; 42:100896.

PMID: 39624483 PMC: 11609321. DOI: 10.1016/j.bbih.2024.100896.


Antibody immune responses and causal relationships in four immune skin diseases: Evidence from Mendelian randomization and Bayesian Weighting (Antibody Responses in Skin Diseases: MR & Bayesian).

Li X, Chen S, Wu Y, Qiu G, Cheng S, Lan H Skin Res Technol. 2024; 30(8):e13875.

PMID: 39120064 PMC: 11311118. DOI: 10.1111/srt.13875.


One-year follow-up of young people with ME/CFS following infectious mononucleosis by Epstein-Barr virus.

Pricoco R, Meidel P, Hofberger T, Zietemann H, Mueller Y, Wiehler K Front Pediatr. 2024; 11:1266738.

PMID: 38304441 PMC: 10830704. DOI: 10.3389/fped.2023.1266738.


IgG Antibody Responses to Epstein-Barr Virus in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Their Effective Potential for Disease Diagnosis and Pathological Antigenic Mimicry.

Fonseca A, Szysz M, Ly H, Cordeiro C, Sepulveda N Medicina (Kaunas). 2024; 60(1).

PMID: 38256421 PMC: 10820613. DOI: 10.3390/medicina60010161.


References
1.
Jason L, Corradi K, Torres-Harding S, Taylor R, King C . Chronic fatigue syndrome: the need for subtypes. Neuropsychol Rev. 2005; 15(1):29-58. DOI: 10.1007/s11065-005-3588-2. View

2.
Houen G, Trier N . Epstein-Barr Virus and Systemic Autoimmune Diseases. Front Immunol. 2021; 11:587380. PMC: 7817975. DOI: 10.3389/fimmu.2020.587380. View

3.
Lunemann J, Jelcic I, Roberts S, Lutterotti A, Tackenberg B, Martin R . EBNA1-specific T cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN-gamma and IL-2. J Exp Med. 2008; 205(8):1763-73. PMC: 2525578. DOI: 10.1084/jem.20072397. View

4.
Blomberg J, Rizwan M, Bohlin-Wiener A, Elfaitouri A, Julin P, Zachrisson O . Antibodies to Human Herpesviruses in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients. Front Immunol. 2019; 10:1946. PMC: 6702656. DOI: 10.3389/fimmu.2019.01946. View

5.
Naviaux R, Naviaux J, Li K, Bright A, Alaynick W, Wang L . Metabolic features of chronic fatigue syndrome. Proc Natl Acad Sci U S A. 2016; 113(37):E5472-80. PMC: 5027464. DOI: 10.1073/pnas.1607571113. View